Teva Pharms Usa Inc Company Profile
What is the competitive landscape for TEVA PHARMS USA INC
TEVA PHARMS USA INC has thirty-two approved drugs.
There are nine tentative approvals on TEVA PHARMS USA INC drugs.
Drugs and US Patents for Teva Pharms Usa Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa Inc | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 214549-002 | Feb 11, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa Inc | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214126-001 | Jul 28, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa Inc | RISPERIDONE | risperidone | POWDER;INTRAMUSCULAR | 214068-004 | Dec 5, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa Inc | BREXPIPRAZOLE | brexpiprazole | TABLET;ORAL | 213692-006 | Aug 11, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Usa Inc | LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209920-001 | Jan 18, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa Inc | RISPERIDONE | risperidone | POWDER;INTRAMUSCULAR | 214068-001 | Dec 5, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

